The Effect of Renal Denervation on Renal Flow in Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many studies have studied the effect and safety of renal denervation. However, it remains unknown what the exact mechanism behind renal denervation is. It can be hypothesized that a difference in renal blood flow occurs after treatment. In the light of this ignorance, current study will investigate whether renal denervation leads to a difference in renal blood flow after treatment with renal denervation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Renal Denervation on Biological Variables

NCT01427049

Hypertension

COMPLETED

The Dutch National Renal Denervation Registry

NCT02482103

Hypertension

UNKNOWN

Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension

NCT01850901

Hypertension Chronic Kidney Disease

COMPLETED PHASE3

Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension

NCT01834118

Hypertension, Resistant to Conventional Therapy

COMPLETED

Renal Denervation in Patients With Refractory Hypertension

NCT00753285

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients undergoing renal denervation

patients diagnosed with resistant hypertension, eligible to undergo renal denervation

Group Type EXPERIMENTAL

Renal Denervation

Intervention Type PROCEDURE

Flowmeasurements will be performed before and after renal denervation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renal Denervation

Flowmeasurements will be performed before and after renal denervation

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

flowmeasurements

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individual is scheduled to undergo renal denervation as standard patient care for resistant hypertension.
* Individual is diagnosed with resistant hypertension. Secondary causes and a white coat hypertension are actively excluded.
* Individual is ≥18 years of age.
* Individual agrees to have all study procedures performed, and is competent and willing to provide written informed consent to participate in this clinical study.

Exclusion Criteria

* Individual is excluded from treatment with pRDN .
* Individual has an estimated glomerular filtration rate (eGFR) of \<30mL/min/1.73m2, using the MDRD calculation.
* Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.
* Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia or significant anaemia).
* Individual is pregnant, nursing or planning to be pregnant.
* Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No